Eisai (ESAIY) is seeking to begin clinical trials on a second Alzheimer’s disease treatment next year, following up on the recent U.S. approval of lecanemab as its first, Nikkei Asia’s Noriyuki Takada, Taito Kurose, and Hinako Banno report. The Fly notes that Biogen (BIIB) and Eisai won full FDA approval of Leqembi earlier this month.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
- Biogen price target lowered to $357 from $380 at BMO Capital
- Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Inches Closer to FDA Approval
- Biogen price target raised to $341 from $332 at RBC Capital
- Biogen shares little changed after resumption of trade